Business Daily from THE HINDU group of publications
Monday, Sep 25, 2006
ePaper
Business Daily from THE HINDU group of publications Monday, Sep 25, 2006 ePaper |
|
|
|
|
|
|
|
Marketing
-
New Products & Services Industry & Economy - Health New low-cost Hepatitis-B vaccine unveiled Our Bureau
Cheaper remedy IIL is expected to price its Hepatitis-B vaccine at around 40 per cent lower than other Hepatitis-B vaccines currently in the market This is expected to make it more affordable and also ensure its wider availability
Hyderabad , Sept. 24 Giving both the Indian private sector players and multinationals into production and marketing of Hepatitis-B vaccine a run for their money, the public sector player National Dairy Development Board (NDDB) has launched its low-cost recombinant DNA Hepatitis-B vaccine under the brand Elovac-B. The vaccine is indigenously manufactured by Human Biologicals Institution (HBI) at its facility located at Gachibowli here. HBI is a division of Indian Immunologicals Ltd (IIL), which is a wholly owned subsidiary of NDDB.
More vaccines
Addressing newspersons on the eve of launching the product here, the IIL Managing Director, Mr K.V. Balasubramaniam, said the institute would also be coming out soon with more human vaccines such as measles, DPT, TT and combination vaccines. While vaccine for measles would be launched before the year-end, the DPT vaccine would hit the market before the fiscal-end. The combination vaccine is expected to be in the market during the next fiscal, he said.
Cheaper price
Mr Balasubramaniam said IIL would be pricing its Hepatitis-B vaccine around 40 per cent lower than the products of the Indian private sector manufacturers and MNCs currently in the market. IIL would be making its products available through the vast network of over 2,000 Abhay Clinics across the country, apart from institutional channels. "This idea is not only to help ensure availability of Hepatitis-B vaccine to the large population across the country at highly affordable prices but also to ensure greater availability of the vaccine," he said.
Elovac-B
Further, he said Elovac-B would significantly gain from the Government's proposal to include Hepatitis-B vaccine in the Extended Programme of Immunisation (EPI), which is expected shortly. IIL has a manufacturing capacity of 200-million doses of Elovac-B at the facility set up around Rs 50 crore. He said that Elovac-B offers purity exceeding specifications provided by the regulatory authorities, and hence ensures best protection.
More Stories on : New Products & Services | Health
Article E-Mail :: Comment :: Syndication :: Printer Friendly Page
|
Stories in this Section |
|
|
The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription Group Sites: The Hindu | The Hindu ePaper | Business Line | Business Line ePaper | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |
Copyright © 2006, The
Hindu Business Line. Republication or redissemination of the contents of
this screen are expressly prohibited without the written consent of
The Hindu Business Line
|